$3.37
+0.38 (+12.71%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PYXS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 8 tracked-famous managers (MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, +3 more) · FINRA short interest 4.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid TumorsNCT06795412Number of Participants who Experience a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: PYX-201, pembrolizumab | Advanced Solid Tumors | 220 | 2027-12-06 | in 473 d | 2026-05-04 |
| A Study of PYX-201 in Advanced Solid TumorsNCT05720117Number of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose EscalationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PYX-201 | Solid Tumor, Advanced Solid Tumor | 330 | 2027-04-25 | in 248 d | 2026-06-30 |
| Study of PYX-106 in Solid TumorsNCT05718557Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: PYX-106 | Solid Tumor | 47 | May 2026 | — | 2025-08-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19